The subtle but significant power shift happening in pharma decisions. Observing the critical role patient advocacy groups play in shaping drug approval outcomes, especially for rare diseases. The real debate: does the formal advisory committee meeting (adcom) or a passionate public forum deliver the necessary leverage for patients? This insight drops essential knowledge on where patient voices pack the biggest punch at the FDA. 🤔 #PatientAdvocacy #FDA #DrugApproval #RareDisease #HealthPolicy - @dansfera